OptiBiotix Health (OPTI) AI Stock Analysis

• Market Cap: £6.09M
• Dividend Yield: N/A
• Average Volume (3M): 268.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 103,300,300
• 10 Day Avg. Volume: 266,472
• 30 Day Avg. Volume: 268,800
• PEG Ratio: 0.53
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 20.26
• P/FCF Ratio: -9.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: 6.50p ▼(-3.70% Downside)

The score is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.

OptiBiotix Health Business Overview & Revenue Model

Company Description

OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; WellBiome, a functional fibre and mineral blend that supports health & wellbeing by promoting the diversity of the gut microbiome; and Sweetbiotix, a sweetener for use in food and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. OptiBiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.

How the Company Makes Money

OptiBiotix Health Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.15M	870.00K	644.00K	457.00K	2.21M	1.52M
Gross Profit	420.00K	331.00K	320.00K	244.00K	1.12M	879.82K
EBITDA	-67.00K	-2.06M	-1.84M	2.75M	6.51M	6.31M
Net Income	-191.00K	-1.80M	-2.04M	2.59M	6.26M	5.80M
Balance Sheet
Total Assets	9.15M	9.04M	9.40M	11.55M	20.14M	13.70M
Cash, Cash Equivalents and Short-Term Investments	1.30M	739.00K	635.00K	1.05M	2.01M	864.68K
Total Debt	0.00	0.00	0.00	0.00	819.36K	771.76K
Total Liabilities	732.00K	647.00K	532.00K	643.00K	1.97M	1.85M
Stockholders Equity	8.42M	8.40M	8.87M	10.90M	18.14M	11.82M
Cash Flow
Free Cash Flow	-1.92M	-1.77M	-1.53M	-1.28M	-1.76M	-1.28M
Operating Cash Flow	-1.92M	-1.77M	-1.53M	-1.11M	-1.56M	-927.96K
Investing Cash Flow	1.24M	587.00K	1.11M	-331.00K	-193.51K	-350.35K
Financing Cash Flow	714.00K	1.28M	0.00	485.00K	2.90M	1.69M

OptiBiotix Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£7.59M	-0.63	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SBTX	50 Neutral	£55.64M	-65.15	-11.24%	―	283.74%	78.57%
TCF	45 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
OPTI	43 Neutral	£6.09M	-42.14	-2.42%	―	―	―
CIZ	43 Neutral	£6.14M	-5.54	-433.59%	―	―	―
NFX	42 Neutral	£6.12M	-0.67	-153.80%	―	―	-616.67%

OptiBiotix Health Corporate Events

OptiBiotix Health Enhances SweetBiotix Production with New Enzymatic Process

OptiBiotix Health has announced significant advancements in the production of its SweetBiotix® product line, which consists of natural, high-fiber, low-calorie sweeteners designed to replace sugar and artificial substitutes. The company has developed a new enzymatic process that increases yield and purity, reduces production costs, and enhances the taste profile of SweetBiotix products. This innovation not only strengthens OptiBiotix’s market position by addressing health concerns associated with sugar substitutes but also opens up new partnership opportunities with sugar producers. The breakthrough is expected to boost investor confidence and expand the commercial potential of SweetBiotix products.

OptiBiotix Secures First Major Order with European Weight Management Firm

OptiBiotix Health has announced its first order from a well-known weight management company for its SlimBiome® and WellBiome® products, marking a significant step in its strategy to provide private label products. This order highlights the growing interest in natural alternatives to GLP1 in the weight management market, which is projected to grow significantly in the coming years. The company’s collaboration with international brands like Hydroxycut and LightLife further strengthens its position in the industry, potentially boosting future sales and shareholder value.